Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Volume 356, Issue 9232, 2 September 2000, Pages 802-807

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial.

This research paper show the혻positive effect of immunotherapy for cancer patients.


Postsurgical recurrence of hepatocellular carcinoma (HCC=liver cancer) is frequent and fatal. Adoptive immunotherapy is active against HCC. We assessed whether postoperative immunotherapy could lower the frequency of recurrence.


Between 1992 and 1995, we did a randomised trial in which 150 patients who had undergone curative resection for HCC were assigned adoptive immunotherapy (n=76) or no adjuvant treatment (n=74). Autologous lymphocytes activated vitro with recombinant interleukin-2 and antibody to CD3 were infused five times during the first 6 months. Primary endpoints were time to first recurrence and recurrence-free survival and analyses were by intention to treat.

Effect on prevention recurrence through Immunotherapy

Adoptive immunotherapy is a safe, feasible treatment that can lower recurrence and improve recurrence-free outcomes after surgery for HCC. Adoptive immunotherapy is no longer thought to be useful because clinical success has been confined to melanoma, renal cancer, and lymphoma.
– The recurrence rate after liver cancer surgery is 75~80% generally.
– whereas the recurrence rate after both the surgery and immunotherapy.
– Control group – 74, Immunotherapy group – 76 of 150 patients after hepatectomy, randomized trial
– After 2weeks, 3weeks, 4weeks, 3months, 6months after operation. – total 5 times immunotherapy.
[Adoptive혻immunotherapy decreased the frequency of recurrence by 18% compared with controls and first recurrence was delayed for 14 months.]


–혻Immunotherapy Group
Recurrence free – 41%
AVG. of first recurrence about 33 months
–혻Control Group
Recurrence – 23%
AVG. of first recurrence about 19 month
Keyword :혻Adoptive immunotherapy ,혻Cancer spread, Overall recurrence, Early recurrence, Local recurrence, Extensive recurrence, Distant metastasis, Multicentric tumour


Source :

Related Articles